Eyepoint Pharmac Stock Price, News & Analysis

On November 19, 2020, EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a virtual roundtable discussion on December 4, 2020, at 12:00 p.m. ET, focusing on local drug delivery for wet age-related macular degeneration (AMD) and EYP-1901, a potential six-month sustained delivery therapy. Esteemed retina specialists, including Robert Avery, M.D., and Elias Reichel, M.D., will participate. Interested parties can access the event by phone or via a live webcast on the company's website.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced positive data for its ophthalmic products YUTIQ and DEXYCU during the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. The second Phase 3 trial for YUTIQ showed a significantly lower recurrence rate of uveitis (46.5% vs. 75%). A multicenter study confirmed DEXYCU's effectiveness in reducing inflammation after cataract surgery, while a comparison study indicated DEXYCU's superiority over traditional eye drops in pain control and patient preference. These findings support the long-term advantages of both products.

On November 10, 2020, EyePoint Pharmaceuticals (NASDAQ: EYPT) announced four abstracts featuring its products YUTIQ® and DEXYCU® presented at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting from November 13-15, 2020.

The presentations include:

• YUTIQ: Phase 3 trial results showing 36-month anti-inflammatory activity.
• DEXYCU: Studies on patient preference and anti-inflammatory efficacy.

These advancements underline EyePoint's commitment to innovative ophthalmic solutions.

EyePoint Pharmaceuticals reported total revenues of $15.7 million for Q3 2020, a significant increase from $2.5 million in Q3 2019. The net product revenues reached $5.8 million with $3.5 million from YUTIQ and $2.3 million from DEXYCU. Customer demand surged over 120% for DEXYCU and over 5% for YUTIQ. The company is on track to file an IND for EYP-1901, targeting wet AMD, by year-end. Cash reserves stood at $30.5 million. A debt facility amendment waiving certain revenue covenants was also announced.

EyePoint Pharmaceuticals (EYPT) will release its third quarter 2020 results on November 5, 2020, followed by a conference call at 8:30 AM ET. The call can be accessed via phone or a live webcast on their corporate website. EyePoint is focused on developing innovative ophthalmic products, including DEXYCU®, the first approved intraocular treatment for postoperative inflammation, and YUTIQ®, a three-year treatment for chronic non-infectious uveitis. Their pipeline includes EYP-1901, targeting wet age-related macular degeneration.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced an amendment to its debt facility with CRG Servicing, waiving the net product revenue covenant for DEXYCU® and YUTIQ® for the year ending December 31, 2020. The revenue covenant for December 31, 2021, is reduced from $80 million to $45 million, reflecting a recovery in customer demand post-COVID-19. As of September 30, 2020, the company had approximately $28.7 million in cash. This amendment acknowledges encouraging recovery trends in customer demand and commercial progress.

EyePoint Pharmaceuticals (EYPT) reported estimated net product revenues for Q3 2020 between $5.5 and $5.9 million, a significant increase from $3.7 million in Q2 2020, as healthcare facilities resumed operations after COVID-19 closures.

Driving this growth was customer demand for YUTIQ and DEXYCU, with estimated revenues of $3.4-$3.5 million and $2.1-$2.4 million respectively. Demand for YUTIQ units increased to 450, while DEXYCU saw a rise to 4,700 units in Q3 2020.

EyePoint Pharmaceuticals (NASDAQ:EYPT) will have CEO Nancy Lurker present at two virtual conferences this September. The Cantor Virtual Healthcare Conference is scheduled for September 15 at 4:40 PM Eastern Time, followed by the H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 2:00 PM Eastern Time. A live webcast and replay will be accessible on their Investors page for 90 days. EyePoint specializes in innovative ophthalmic products, with commercial offerings including DEXYCU® and YUTIQ®, as well as pipeline developments using their Durasert® technology.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has entered a purchase and marketing agreement with Vantage Outsourcing for its ophthalmic product DEXYCU®, enabling broader access in over 25 states. This collaboration aims to integrate DEXYCU into surgical protocols for treating ocular inflammation related to cataract surgery. President Nancy Lurker emphasizes the partnership's potential for expanding their reach within the cataract surgery market. Vantage Outsourcing's services will enhance the postoperative experience for patients by providing a long-lasting anti-inflammatory treatment.